Prognostic marker

• Main Authors: SCHINBERG THOMAS J, LIN HUIMING, SULLIVAN, DAVID, R, MACKEL PETER J, HORVATH, LEWIS, G
• Format: Patent
• Language: Chinese; English
• Published: 13.06.2025
• Subjects: HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TESTING

The present invention relates to a method for determining or predicting the prognosis and survival of a subject having prostate cancer comprising determining the levels of at least three lipid biomarkers in a biological sample obtained from said subject, and compositions and kits for use in said method, wherein the at least three lipid biomarkers are selected from the group consisting of ceramide (d18: 1/18: 0), ceramide (d18: 1/22: 0), ceramide (d18: 1/24: 0), ceramide (d18: 1/24: 1), ceramide (d20: 1/24: 0), ceramide (d20: 1/24: 1), phosphatidylcholine (16: 0/16: 0) and sphingomyelin (d18: 1/16: 0). 本发明涉及用于确定或预测具有前列腺癌的受试者的预后和存活的方法以及用于用在所述方法中的组合物和试剂盒，所述方法包括确定从所述受试者得到的生物样品中的至少三种脂质生物标志物的水平，其中所述至少三种脂质生物标志物选自神经酰胺(d18:1/18:0)、神经酰胺(d18:1/22:0)、神经酰胺(d18:1/24:0)、神经酰胺(d18:1/24:1)、神经酰胺(d20:1/24:0)、神经酰胺(d20:1/24:1)、磷脂酰胆碱(16:0/16:0)和鞘磷脂(d18:1/16:0)。